AI Article Synopsis
- The ENGIP-I study examined how effective and safe itopride is for patients with gastro-oesophageal reflux disease (GERD).
- Significant improvements in heartburn frequency, severity, and regurgitation were noted after just 3 days of treatment.
- The study found that itopride was well tolerated by patients and is considered a favorable option for treating GERD.
Article Abstract
The ENGIP-I study was conducted to investigate the efficacy, and safety of itopride in patients of gastro-oesophageal reflux disease. There were significant reductions in heartburn frequency, heartburn severity, gastro-oesophageal regurgitation frequency at day 3 only. ENGIP-I study concluded that itopride was well tolerated by patients and appears to be the drug of choice in patients with gastro-oesophageal reflux disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
engip-i study
12
patients gastro-oesophageal
8
gastro-oesophageal reflux
8
reflux disease
8
evaluation gastro-intestinal
4
gastro-intestinal prokinetic
4
prokinetic engip-i
4
study engip-i
4
study conducted
4
conducted investigate
4
Similar Publications
Evaluation of new gastro-intestinal prokinetic (ENGIP-I) study.
J Indian Med Assoc
October 2005
JB Chemicals & Pharmaceuticals Limited, Mumbai 400030.
Article Synopsis
- The ENGIP-I study examined how effective and safe itopride is for patients with gastro-oesophageal reflux disease (GERD).
- Significant improvements in heartburn frequency, severity, and regurgitation were noted after just 3 days of treatment.
- The study found that itopride was well tolerated by patients and is considered a favorable option for treating GERD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!